SE8701921L - NEW PHARMACEUTICAL APPLICATION - Google Patents

NEW PHARMACEUTICAL APPLICATION

Info

Publication number
SE8701921L
SE8701921L SE8701921A SE8701921A SE8701921L SE 8701921 L SE8701921 L SE 8701921L SE 8701921 A SE8701921 A SE 8701921A SE 8701921 A SE8701921 A SE 8701921A SE 8701921 L SE8701921 L SE 8701921L
Authority
SE
Sweden
Prior art keywords
tissue
new pharmaceutical
pharmaceutical application
medicament
damage
Prior art date
Application number
SE8701921A
Other languages
Swedish (sv)
Other versions
SE8701921D0 (en
Inventor
Jr H Berger
C J Frangakis
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/862,057 external-priority patent/US4976959A/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of SE8701921D0 publication Critical patent/SE8701921D0/en
Publication of SE8701921L publication Critical patent/SE8701921L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Tissue plasminogen activator (t-PA), optionally together with superoxide dismutase (SOD), is used to manufacture a medicament for use in the inhibition of damage to jeopardised tissue during blood reperfusion. The medicament is for preventing damage to tissue following ischaemic attack, e.g. in myocardial tissue, when blood supply is restored.
SE8701921A 1986-05-12 1987-05-11 NEW PHARMACEUTICAL APPLICATION SE8701921L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86204686A 1986-05-12 1986-05-12
US06/862,057 US4976959A (en) 1986-05-12 1986-05-12 T-PA and SOD in limiting tissue damage

Publications (2)

Publication Number Publication Date
SE8701921D0 SE8701921D0 (en) 1987-05-11
SE8701921L true SE8701921L (en) 1987-11-13

Family

ID=27127662

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8701921A SE8701921L (en) 1986-05-12 1987-05-11 NEW PHARMACEUTICAL APPLICATION

Country Status (13)

Country Link
JP (1) JPH0680015B2 (en)
AU (1) AU600724B2 (en)
BE (1) BE1001425A4 (en)
CH (1) CH672989A5 (en)
DE (1) DE3715662A1 (en)
DK (1) DK237187A (en)
FR (1) FR2600895B1 (en)
GB (1) GB2194886B (en)
IE (1) IE59895B1 (en)
LU (1) LU86875A1 (en)
NL (1) NL8701113A (en)
NZ (1) NZ220260A (en)
SE (1) SE8701921L (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0780784B2 (en) * 1987-10-23 1995-08-30 宇部興産株式会社 Myocardial ischemic injury therapeutic agent based on microcirculatory disorder
NZ230808A (en) * 1988-10-24 1993-04-28 Squibb & Sons Inc Pharmaceutical compositions and combinations containing an angiotensin-converting enzyme inhibitor and a thrombolytic agent
DE4038563A1 (en) * 1990-12-04 1992-06-11 Gruenenthal Gmbh USE OF SUPEROXIDE DISMUTASES FOR PROPHYLAXIS AND / OR TREATMENT OF ORGAN FAILURE IN RISK PATIENTS WITH POLYTRAUMA
DE19518625C2 (en) * 1995-05-24 1997-08-07 Buescher Pebueso Beton Process for sealing concrete pipes and a concrete pipe suitable for carrying out the process
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US7175679B2 (en) 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US7576174B2 (en) 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
EP1300418A1 (en) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US7517529B2 (en) 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
AU2006266609C1 (en) 2005-07-05 2011-10-27 Biotempt B.V. Treatment of tumors
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
US8652476B2 (en) 2009-07-27 2014-02-18 Niigata University Pharmaceutical composition for treating ischemic events
WO2011013668A1 (en) * 2009-07-27 2011-02-03 国立大学法人新潟大学 Pharmaceutical composition for treatment of ischemic events

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8003402A (en) * 1980-06-11 1982-01-04 Leuven Res & Dev Vzw NEW PLASMINOGEN ACTIVATOR AND PHARMACEUTICAL PREPARATION WITH THROMBOLYTIC ACTION.
EP0112122B1 (en) * 1982-12-14 1991-08-28 South African Inventions Development Corporation Plasminogen activator
JPS59196824A (en) * 1983-04-21 1984-11-08 Kowa Co Adsorption inhibitor
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
AU569429B2 (en) * 1985-05-28 1988-01-28 Wellcome Foundation Limited, The Aqueous acidic tissue plasminogen activator parenternal formulation
AU6334586A (en) * 1986-05-15 1987-12-01 Emory University Composition and method for treating a thrombus and embolus

Also Published As

Publication number Publication date
CH672989A5 (en) 1990-01-31
AU600724B2 (en) 1990-08-23
FR2600895A1 (en) 1988-01-08
IE871210L (en) 1987-11-12
NZ220260A (en) 1990-07-26
DE3715662A1 (en) 1987-11-19
JPH0680015B2 (en) 1994-10-12
LU86875A1 (en) 1988-01-20
DK237187A (en) 1987-11-13
IE59895B1 (en) 1994-04-20
FR2600895B1 (en) 1993-12-24
DK237187D0 (en) 1987-05-11
AU7270487A (en) 1987-11-19
SE8701921D0 (en) 1987-05-11
NL8701113A (en) 1987-12-01
BE1001425A4 (en) 1989-10-31
GB2194886A (en) 1988-03-23
GB8711058D0 (en) 1987-06-17
JPS6322026A (en) 1988-01-29
GB2194886B (en) 1990-04-25

Similar Documents

Publication Publication Date Title
SE8701921D0 (en) NEW PHARMACEUTICAL APPLICATION
FI19991893A (en) Controlled release of budesonide for oral administration and use of budesonide
ATE172359T1 (en) COLD STERILIZER WITH EXTENDED ACTIVITY
DK0698389T3 (en) Controlled release matrix for pharmaceutical preparations
DE3864020D1 (en) ARRANGEMENT FOR REMOVAL OF ACTIVE AGENTS, LOCALLY USED AGAINST SOLID TUMORS.
DE60040345D1 (en) PROCESS FOR PREPARING A REVERSIBLE INACTIVE, ACIDIFIED PLASMINE COMPOSITION
DK463989A (en) PHARMACEUTICAL ACTIVE COMBINATION
IS3284A7 (en) Process for the preparation of N1-substituted benzimidazole derivatives for therapeutic use
SE8602405L (en) NEW FORMULATION
DK261490D0 (en) NEW PHARMACEUTICAL COMPOUND
DK0460062T3 (en) Huperzin A analogues
TW337997B (en) Pharmaceutical preparation containing plasminogen activators
DE3677395D1 (en) PHARMACEUTICAL COMPOSITION MADE OF GUAR RUBBER AND OTHER ANTIACIDA TO PROTECT OESO-GASTRO-DUODENAL Mucous Membrane.
ES2013500A6 (en) Variants of plasminogen activators and processes for their production.
SE9602644D0 (en) New use
ES2000033A6 (en) Liquid stable anthelmintic and fungicidal composition based on bithionol sulfoxide.
AR030647A1 (en) PHARMACEUTICAL COMPOSITION WITH SPECIFIC WATER ACTIVITY
DK1019037T3 (en) Drug containing delta-aminolevulinic acid
DK0499679T3 (en) Therapeutic agent for diabetic gangrene
KR890701732A (en) Improved tissue plasminogen activator
GR77250B (en)
EP0386240A4 (en) Novel polypeptide compounds
TR200102221T2 (en) Use of moxonidine for treatments after a heart attack
IT1206281B (en) Tissue plasminogen activator to remove blood clots
MX9710126A (en) Substituted compounds with sulphonamide, process for its preparation, its use as a medicament or diagnostic agent as well as pharmaceutical preparations.